Foundation Medicine teams with IMS on precision medicine service

Foundation Medicine and IMS Health have teamed up to offer a precision medicine service. The alliance brings together Foundation Medicine's cancer genomics database and IMS' real-world evidence platform, a combination the partners think can enable the effective use of more targeted therapies.

Analyst: R&D time pressures mean clinical trial tech and automation are finally taking off

Biopharma companies may finally be fully embracing the wealth of clinical trial technologies now available. The trend, according to the analyst who observed it, is partly a result of the pressure on R&D teams to hustle drugs to market as quickly as possible while also generating the pharmacoeconomic data payers now demand.

Google to pair its cloud-computing power with Broad's analytic tools

Google has signed up a high-profile collaborator to work on its burgeoning cloud genomics platform. The agreement will see the Broad Institute of MIT and Harvard work with Google to create new tools that pair their respective strengths in data analysis and cloud computing, starting with the offering of GATK as a service.

Google steps up wearables plan with clinical trial-focused wristband

Google has revealed its pitch to establish wearables as a cornerstone of clinical trials. The wristband health tracker is aimed squarely at the clinical trial and healthcare sectors, setting it apart from consumer-focused rivals from Apple and Fitbit.

Eisai strikes extensive multiyear IT outsourcing deal with Accenture

Eisai has become the latest in a long line of companies to look to IT outsourcing for cost savings. The drugmaker has handed responsibility for the maintenance, operation and monitoring of much of its IT infrastructure in Japan and the U.S. to Accenture in a pair of long-term deals.

SEC starts pursuit of biotech-focused hacking ring

The Securities and Exchange Commission (SEC) is going after the biotech-focused hacking ring known as FIN4. Details of the group first emerged last year when security company FireEye reported on how it was breaking into email accounts in search of stock-moving news nuggets, a modus operandi that has put it in the crosshairs of the SEC.

Zymergen snags $44M for data-driven rethink of fermentation

Zymergen raised $44 million in a Series A round to develop its data-driven approach to improving microbe-based manufacturing.

Pfizer's Lipset plots path to mainstream acceptance of experimental trial techs

Almost exactly four years after Pfizer wowed the clinical trial sector with its plans for a virtual, fully-remote study, one of the people behind the project has outlined how the industry is continuing to move the methods it pioneered toward the mainstream.

REMS website overhauled by FDA to simplify access to information

The FDA has overhauled its Risk Evaluation and Mitigation Strategies website to make it easier to find up-to-date information. The new version moves details of whether REMS apply to a drug, what components are in place and when they were last updated to the forefront, ending the need for users to dig through a database to find information.

GSK gives Altius $95M and a mission to hire computer scientists for 'living genome' research

GlaxoSmithKline is placing a $95 million wager on the significance of the "living genome," a term for the noncoding DNA that appear to regulate how genes function in different cells, states of disease and environments. The initiative will lean heavily on computer scientists, who will make up some of the 40 to 80 researchers that will be hired using the Glaxo funds.

DIA starts with a flurry of hires, deals and product updates

With the clinical trial community gathering for DIA 2015, eClinical tech vendors have been rolling out releases about their new tools, hires and deals. Here we round up a batch of notable news, including a new hire at Clinical Ink, deals for DocuSign and a visit to the FDA by Nextrials.

FDA digs into PatientsLikeMe's data to add patients' voices to safety monitoring

PatientsLikeMe has pulled off a major coup. The patient-networking website added FDA to its roster of A-list clients this week in a deal that sees it provide the regulator with access to the 110,000 adverse event reports filed by its 350,000 members.

The search for exceptional responders in tumor sequencing databases

The Washington Post has taken a look at how hospitals are using genetic tumor databases to find exceptional responders to cancer drugs.

Takeda taps Sanford for robotics, 3-D modeling skills in heart failure pact

Sanford-Burnham Medical Research Institute is about to apply its robotics and 3-D modeling skills to the discovery of molecules to treat heart failure. Takeda is bankrolling the two-year program as part of its broader collaboration The Sanford Consortium for Regenerative Medicine.

Allergan slashes laptop use in full-throttle mobile push

The long-heralded, little-seen death of the laptop may actually be happening at Allergan. A push to restrict staffers to one device and the arrival of Microsoft Office on the Apple iPad reportedly drove a 10% year-on-year decline in laptop use at the company.

EHR-enabled data dive links stomach blockbusters to heart attacks

An electronic health record-enabled data dive has turned up links between proton pump inhibitors and a 16% to 20% increase in the risk of heart attack.

J&J teams with Emulate to use organ-on-a-chip technology in R&D programs

Johnson & Johnson has teamed up with Emulate to incorporate organ-on-a-chip technology into its R&D programs. The project will allow J&J to assess whether the technology can do a better job than animal models at assessing pulmonary thrombosis and predicting liver toxicity.

Twist on IT hiring spree as Illumina backs $37M fundraising round

Twist Bioscience is set to grow its headcount by 50% after it raised $37 million from Illumina and other investors to move its DNA synthesis technology toward commercialization. And IT hires feature heavily in the startup's plans, with half of the current job openings relating to bioinformatics, Python databases and other niches in the field.

Amazon, Google duke it out for control of cloud genomics

The battlefront between Amazon and Google covers a diverse range of fields, from online search and advertising, to smartphones and shopping. Increasingly, genomics is emerging as another hotspot, with both companies scrambling to establish themselves as the place to store and analyze DNA data.

10X Genomics poaches David Jaffe from the Broad Institute

10X Genomics has lured David Jaffe away from the Broad Institute. Jaffe spent 15 years at Broad, during which time he developed methods for genome assembly and variant analysis.